Brexucabtagene Autoleucel's Impact on MCL Treatment Landscape: Luhua Wang, MD

The professor from The University of Texas MD Anderson Cancer discussed the impact that brexucabtagene autoleucel's approval has had on mantle cell lymphoma.

Current Limitations of CAR T-Cell Therapy in Multiple Myeloma: Muhamed Baljevic, MD

The assistant professor from University of Nebraska Medical Center discussed the current limitations of CAR T-cell therapy in multiple myeloma.

Advantages of mRNA-Based Gene Therapies

Jake Becraft, PhD, chief executive officer and cofounder, Strand Therapeutics, discussed the company’s technology and focus on mRNA therapies.